- Atlas Oncology Partners is a value-based oncology enablement platform that embeds interdisciplinary care teams into community oncology practices and assumes full medical cost risk to improve patient outcomes and experience.
NASHVILLE, Tenn.–(BUSINESS WIRE)–Atlas Oncology Partners today announced the closing of its Series A financing. Atlas was founded by Rubicon Founders, a healthcare investment firm focused on building and growing companies that transform the way people receive care. The financing round was led by Flare Capital Partners with significant participation from Rubicon Founders.
The $28 million funding round will be used to expand Atlas’ geographic footprint with more oncology practice partners and invest in clinical and operational infrastructure.
Cancer care is often fragmented, forcing patients to navigate multiple providers while managing complex clinical and social needs. Atlas was founded to address these challenges by embedding interdisciplinary care teams–providers, nurses, patient navigators, and social workers–directly into oncology practices, enabling coordinated, patient-centered care during and beyond active treatment.
“From the moment of diagnosis, patients can feel overwhelmed by the complexity of cancer care,” said Kate Barnard Roberts, President and Co-Founder of Atlas Oncology Partners. “Atlas was built to simplify that experience by embedding holistic, coordinated support into oncology practices. This investment enables us to scale our model and reach more patients while staying true to our mission of improving quality of life and outcomes.”
Atlas’ model combines patient navigation, psychosocial and supportive care, proactive care coordination, and expanded in-person and virtual clinical access. Atlas assumes full medical cost risk from payors and aligns incentives with a high-value network of medical oncology practice partners. To succeed in these arrangements, Atlas makes investments to support partner operations, leading to high-quality, value-based care that reduces avoidable costs and eases the financial burden on patients.
“We incubated and invested in Atlas Oncology Partners to fundamentally rethink how cancer care is delivered,” said Matt Kim, Partner at Rubicon Founders. “By embedding interdisciplinary teams directly into oncology practices and assuming full medical cost risk, Atlas is building a scalable model that improves outcomes, experience, and affordability.”
“Atlas Oncology Partners is addressing one of the most complex and costly areas of healthcare with a model that is deeply aligned with patients, oncologists, and payers at the forefront of value-based care,” said Ian Chiang, Partner at Flare Capital Partners. “We are excited to lead their Series A and support Atlas as it scales the next-generation value-based oncology model — one that empowers community oncology groups to deliver coordinated, holistic care at scale and drives impactful clinical outcomes for patients and families impacted by cancer.”
About Atlas Oncology Partners
Atlas Oncology Partners is dedicated to delivering uplifting and responsive cancer care during and beyond treatment. By partnering with leading oncologists and taking full medical cost risk, Atlas offers an innovative solution that delivers better care experiences while easing the economic strain of cancer treatment. Learn more at www.atlasoncpartners.com.
About Rubicon Founders
Rubicon Founders is an entrepreneurial healthcare investment firm focused on building and growing transformational companies that create enduring value by transforming the way people receive care. Rubicon Founders brings together a core team of investment, operating, and technology professionals who work to put patients and doctors first. For more information, visit www.rubiconfounders.com.
About Flare Capital Partners
Flare Capital Partners is the leading healthcare technology venture capital firm advancing innovation-driven companies to improve positive health outcomes, broaden care access, and lower healthcare costs. We partner with exceptional founders solving healthcare’s hardest challenges, supporting each with our deep sector expertise, unparalleled industry resources, and proven access to commercial opportunities. Our team of established investors and senior operating executives has invested in 70+ companies and has nearly $1 billion in assets under management. Learn more at www.flarecapital.com.
Contacts
Media Contacts
Emma Nosseir
Chief of Staff, Atlas Oncology Partners
Email: [email protected]
Kelly Ruggiero
Head of Investor Relations, Rubicon Founders
Email: [email protected]
Amanda DiTrolio
Vice President of Marketing & Platform, Flare Capital Partners
Email: [email protected]
